Europäische Union - Deutsch - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - schweine - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

santen sa - levofloxacinum, dexamethasonum - collyre en solution - levofloxacinum 5 mg ut levofloxacinum hemihydricum, dexamethasonum 1 mg ut dexamethasoni natrii phosphas, benzalkonii chloridi solutio 0.10 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas dodecahydricus, natrii citras dihydricus, natrii hydroxidum aut acidum hydrochloridum dilutum ad ph, aqua ad iniectabile, ad solutionem pro 1 ml corresp. phosphas 4.01 mg. - prévention et traitement de l'inflammation ainsi que prévention des infections associées à la chirurgie de la cataracte chez l'adulte - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - hähnchen - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Europäische Union - Deutsch - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - immunologische für canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/1/2020, medi 340505)), virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like a/norway/16606/2021 (medi 355293)), virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like b/austria/1359417/2021 (medi 355293, victoria lineage)) - nasenspray, suspension - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/1/2020, medi 340505)) 70 mio. ffu, virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like a/norway/16606/2021 (medi 355293)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like b/austria/1359417/2021 (medi 355293, victoria lineage)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/phuket/3073/2013-like: b/phuket/3073/2013 (medi 306444, yamagata lineage)) 70 mio. ffu, saccharum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, gelatina hydrolysata, arginini hydrochloridum, natrii hydrogenoglutamas monohydricus, aqua ad iniectabile q.s. ad suspensionem pro 0.2 ml. - aktive immunisierung gegen influenza für kinder und jugendliche im alter von 2-18 jahren - impfstoffe

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

chevita tierarzneimittel-gmbh (3074157) - tauben-paramyxovirus typ 1, stamm 988m, inaktiviert - emulsion zur injektion - tauben-paramyxovirus typ 1, stamm 988m, inaktiviert (38678) 2,5361 hämagglutinationshemmungs-einheit(en) - taube

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

orifarm gmbh (3237116) - fsme-virus, stamm k23, inaktiviert - injektionssuspension in einer fertigspritze - teil 1 - injektionssuspension in einer fertigspritze; fsme-virus, stamm k23, inaktiviert (31420) 1,5 mikrogramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

eurimpharm arzneimittel gmbh (8050167) - fsme-virus, stamm k23, inaktiviert - suspension zur injektion - teil 1 - suspension zur injektion; fsme-virus, stamm k23, inaktiviert (31420) 0,75 mikrogramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

cc - pharma gmbh (8029457) - fsme-virus, stamm k23, inaktiviert - suspension zur injektion in einer fertigspritze - fsme-virus, stamm k23, inaktiviert (31420) 1,5 mikrogramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

kohlpharma gmbh (3216120) - fsme-virus, stamm k23, inaktiviert - injektionssuspension in einer fertigspritze - teil 1 - injektionssuspension in einer fertigspritze; fsme-virus, stamm k23, inaktiviert (31420) 0,75 mikrogramm